Attention! Your ePaper is waiting for publication!
By publishing your document, the content will be optimally indexed by Google via AI and sorted into the right category for over 500 million ePaper readers on YUMPU.
This will ensure high visibility and many readers!
Your ePaper is now published and live on YUMPU!
You can find your publication here:
Share your interactive ePaper on all platforms and on your website with our embed function
The Toxicologist - Society of Toxicology
The Toxicologist - Society of Toxicology
The Toxicologist - Society of Toxicology
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Day 11 and started to recover on Day 18. <strong>The</strong>se changes correlated with statistically<br />
significant increases (p
1434 URINARY BIOMARKER DETECTION OF MELAMINE- CYANURIC ACID-INDUCED KIDNEY DAMAGE IN RATS. Q. Zhang 1 , G. Gamboa da Costa 2 , R. Beger 2 , L. Schnackenberg 2 , J. Sun 2 , L. Pence 2 , S. Bhattacharyya 2 , C. Jacob 2 , R. P. Brown 1 and P. L. Goering 1 . 1 CDRH, U.S. FDA, Silver Spring, MD and 2 NCTR, U.S. FDA, Jefferson, AR. Exposure <strong>of</strong> rats to melamine and cyanuric acid in the feed can result in a dose-dependent increase in formation <strong>of</strong> melamine-cyanuric acid crystals in the kidney. <strong>The</strong> aim <strong>of</strong> this study was to determine if urinary biomarkers <strong>of</strong> acute kidney injury can be used to detect noninvasively renal damage associated with crystal formation in the kidneys <strong>of</strong> melamine-cyanuric acid-exposed rats. Male and female Fischer 344 rats were fed a melamine-cyanuric acid mixed diet at approximately 5, 10 and 15 mg/kg body weight/day for 28 days. Urine samples were collected at 1, 2, 3, 4, 14, and 28 days. A series <strong>of</strong> urinary protein biomarkers (Kim-1, NGAL, osteopontin, alpha-GST, GSTYb1, RPA-1 and clusterin) were measured by MesoScale Discovery multiplex assay system. Urinary metabolites were evaluated by NMR and LC/MS metabolomic assays. <strong>The</strong> results showed that RPA-1 (distal tubule and collecting duct injury biomarker) was elevated at the 10 and 15 mg/kg doses in a timedependent manner; however, there were no changes observed in other urinary protein biomarkers at any other dose or time point. Metabolomic analysis showed increased levels <strong>of</strong> urinary proline on days 3 and 28 in male rats and day 28 in female rats at the 15 mg/kg dose only. An increase <strong>of</strong> urinary hydroxyproline was observed on day 28 in male rats and on day 1 in female rats at 15 mg/kg. Significant renal histopathological changes were observed at the 15 mg/kg dose, although variable levels <strong>of</strong> melamine-cyanurate crystal formation were observable at the lower dose levels. <strong>The</strong>se data indicate that increased levels <strong>of</strong> urinary RPA-1 and various urinary amino acids are seen at doses <strong>of</strong> melamine-cyanuric acid that produce histopathological damage in the kidney. As a result, these endpoints may serve as promising noninvasive urinary biomarkers for the detection <strong>of</strong> acute kidney injury associated with melamine-cyanuric acid exposure. 1435 VALIDATION OF BEST DETECTION METHODS FOR MEASURING OXIDATIVE STRESS. M. B. Kadiiska. NIEHS/NIH, Research Triangle Park, NC. Many techniques now exist that potentially allow the measurement <strong>of</strong> oxidative stress in experimental animal models and humans. <strong>The</strong> concept <strong>of</strong> measuring oxidative stress status in humans has not been approached as a real possibility in clinical practice because standardized methods are not yet established. NIEHS/NIH has taken the lead in organizing and sponsoring the first national and international comprehensive comparative study for determining which <strong>of</strong> the available biomarkers <strong>of</strong> oxidative stress are most specific, sensitive and selective. Investigators from 25 laboratories are participating in this study, called BOSS. <strong>The</strong> goal <strong>of</strong> the BOSS is to validate and find the best markers <strong>of</strong> oxidative stress that are applicable to different oxidative insults and measurable in stored specimens. Antioxidants and various oxidative products <strong>of</strong> lipids, proteins and DNA were measured in blood, plasma and urine <strong>of</strong> experimental animals with three different oxidative insults <strong>of</strong> CCl4 poisoning, ozone exposure, and LPS treatment. It was found that plasma concentrations <strong>of</strong> MDA and F2-isoprostanes (measured by GC/MS) and urinary concentrations <strong>of</strong> isoprostanes (measured with ELISA) were increased in CCl4- and ozone-exposed rats, and LPS-treated mini pigs in a time- and dose-dependent manner. Antioxidants (GSH/GSSG, tocopherols, ascorbic acid, uric acid, and total antioxidant capacity), oxidation products <strong>of</strong> proteins (protein carbonyls, methioninesulfoxidation, and tyrosine oxidative products) and DNA (strand breaks, 8-OH-dG, M1G) were not significantly changed. It is concluded that measurements <strong>of</strong> plasma lipid peroxidation products MDA and isoprostanes (by GC/MS) and urinary isoprostanes (by ELISA or GC/MS) are promising candidates for general biomarkers <strong>of</strong> oxidative stress. Various antioxidants, protein- and DNA-oxidation products are not identified as biomarkers <strong>of</strong> oxidative stress induced by CCl4- , ozone- or LPS- exposures. 1436 STEROID HORMONE PROFILING BY MASS SPECTROMETRY IN RAT BLOOD COLLECTED VIA THE CULEX® AUTOMATED IN VIVO SAMPLING SYSTEM. C. Penno 1, 2 , L. Morawiec 1 , M. Schwald 1 , N. Zamurovic 1 , S. Busch 1 , A. Wolf 1 , F. Pognan 1 , S. Chibout 1 , A. Odermatt 2 and M. Dong 1 . 1 Preclinical Safety, Novartis, Basel, Switzerland and 2 Department <strong>of</strong> Pharmaceutical Sciences, University <strong>of</strong> Basel, Basel, Switzerland. Impaired steroid hormone regulation has been implicated in the pathogenesis <strong>of</strong> multitudinous drug-induced toxicities. A quantitative pr<strong>of</strong>ile <strong>of</strong> steroid hormone metabolites holds great potential to help assessing drug safety, dissecting toxic mechanisms, understanding disease progress and providing rational therapeutic in- 308 SOT 2011 ANNUAL MEETING tervention. A novel LC-MS/MS method has been established to quantify a panel <strong>of</strong> 12 steroid hormones: aldosterone, cortisol, cortisone, corticosterone, 11-dehydrocorticosterone, 11-deoxycorticosterone, 11-deoxycortisol, testosterone, dihydrotestosterone, androstenedione, 17α-hydroxyprogesterone and progesterone (comprising rodent and human metabolites). Steroid metabolites were resolved by liquid chromatography using an Allure Biphenyl (Restek) column and quantified by Agilent 6410 Triple-Q mass spectrometer. <strong>The</strong> method presented excellent dilution linearity for all 12 metabolites and the limits <strong>of</strong> quantitation were ranging from 250 pM for androstenedione to 4 nM for corticosterone. Method validation and measurements were performed in 50 μL <strong>of</strong> rat plasma spiked with calibrators and deuterized internal standards. <strong>The</strong> method was then applied to pr<strong>of</strong>ile timecourse changes <strong>of</strong> steroid hormones in rat plasma. Wistar male rats were connected to the Culex® system through carotid artery or jugular vein. Blood collection was programmed every 3 hours during a 24-hour period. Interim results indicated that changes <strong>of</strong> corticosterone, 11-dehydrocorticosterone, and 11-deoxycortisol followed the known circadian rhythm, suggesting the non-disturbance <strong>of</strong> glucocorticoid pr<strong>of</strong>iles in catheterized rats. Levels <strong>of</strong> testosterone, androstenedione and progesterone were rather constant regardless <strong>of</strong> the day and night shift. <strong>The</strong> other steroid metabolites analyzed were below the detection limit. Samples from additional animals are currently being analyzed to gain a high level <strong>of</strong> statistical power. 1437 SERUM CARDIAC TROPONIN I CONCENTRATION AS AN EARLY BIOMARKER OF MYOCARDIAL HYPERTROPHY IN THE ROSIGLITAZONE OR 3, 3’, 5- TRIIODO-L-THYRONINE TREATED RAT. M. Dunn 1 , D. Coluccio 1 , R. Fernandes 1 , D. Knapp 1 , R. Nicklaus 1 , G. Hirkaler 1 , W. Geng 1 , M. Sanders 1 , T. Singer 2 and I. Mikaelian 1 . 1 Nonclinical Safety, Roche, Nutley, NJ and 2 Nonclinical Safety, Roche, Basel, Switzerland. Sponsor: K. Kolaja. Background: <strong>The</strong> peroxisome proliferator-activated receptor gamma (PPARγ) agonist rosiglitazone has been linked to cardiac hypertrophy in rats and an increased risk <strong>of</strong> myocardial infarction in man. Exclusive to the heart, cardiac troponin (cTn) I is released in response to myocardial damage. Our goal was to investigate the link between cardiac hypertrophy and low level changes <strong>of</strong> serum cTnI concentrations following rosiglitazone or 3,3’,5-triiodo-L-thyronine (T3) treatment in the rat. Methods and Results: Serial blood samples from male rats were evaluated following dosing <strong>of</strong> rosiglitazone (80 mg/kg/day) or T3 (20 μg/kg/day) for 14 or 28 days, with 14 or 27 days <strong>of</strong> recovery. Histopathology and clinical chemistry, including measurement <strong>of</strong> cTnI concentrations with the Singulex Erenna® Ultrasensitive Immunoassay were performed. Compared to aged-matched vehicle treated controls, a treatment-duration dependent increase <strong>of</strong> heart weight to brain weight was observed in both rosiglitazone (10% and 17%) and T3 (21% and 30%) treated groups after 14 and 28 days <strong>of</strong> treatment, respectively, and this cardiac hypertrophy was found to be reversed after the recovery period. Across treatment groups and at all time points, a positive correlation was established between cTnI concentration and the degree <strong>of</strong> cardiac hypertrophy. Significant elevations <strong>of</strong> cTnI were quantified after 14 and 28 days <strong>of</strong> rosiglitazone treatment, in the absence <strong>of</strong> histomorphologic findings. As expected, T3 treatment induced marked and progressive elevations in cTnI concurrent with histiocytic infiltration <strong>of</strong> the myocardium after 14 and 28 days <strong>of</strong> dosing, and necrosis after 28 days <strong>of</strong> dosing. Conclusion: Our results demonstrate the sensitivity <strong>of</strong> low level cTnI concentration changes as indicative <strong>of</strong> myocardial hypertrophy which may occur in the absence <strong>of</strong> histomorphologic findings. <strong>The</strong>se results lend support for serum cTnI concentrations as an early biomarker <strong>of</strong> cardiovascular liability. 1438 CHARACTERISATION OF THE PRODROMAL AND REVERSIBILITY VALUE OF NOVEL RENAL SAFETY BIOMARKERS IN GENTAMICIN-TREATED RATS. J. Wood 1 , A. Shoieb 1 , A. McGuinty 1 , P. Cleall 1 , D. Hardy 1 , D. Collins 1 , C. Dubray 1 , R. Williams 1 , A. Moody 1 , K. Lynch 2 , D. Ennulat 2 , T. Sellars 2 , T. Lambert 2 , S. Beushausen 3 , E. Harpur 4 , M. Guffroy 1 and D. Brees 1 . 1 Pfizer, Sandwich, United Kingdom, 2 GlaxoSmithKline, King <strong>of</strong> Prussia, PA, 3 Pfizer, St. Louis, MO and 4 San<strong>of</strong>i-Aventis, Alnwick, United Kingdom. Sponsor: D. Robinson Gravatt. <strong>The</strong> objectives <strong>of</strong> this ILSI-HESI sponsored study were to further define the value <strong>of</strong> the novel renal biomarkers during the prodromal and reversibility phases <strong>of</strong> renal injury, using Gentamicin as a test toxicant. Gentamicin was administered by subcutaneous injection once daily to groups <strong>of</strong> 10 male Sprague-Dawley rats at 50 mg/kg/day for 1, 4 or 10 days. Overnight urine samples were collected pre-dose (days -7 and -3), on Days 2, 5, 11 (dosing period), and on Days 18, 25, 32 and 39 (recovery period) and analysed for Kim-1, NGAL, Osteopontin, Albumin, Regucalcin, Beta-2-Microglobulin, Cystatin C, Clusterin, GST-α, GST-Yb1, RPA- 1, NAG, Creatinine and Protein. Microscopically, tubular epithelial degeneration/necrosis <strong>of</strong> the proximal convoluted tubules was observed on Day 5, peaked on
Day 11 and started to recover on Day 18. <strong>The</strong>se changes correlated with statistically significant increases (p
- Page 1 and 2:
The Toxicologist Supplement to Toxi
- Page 3 and 4:
The Toxicologist Supplement to Toxi
- Page 5 and 6:
1 BIODEGRADABLE MATERIALS FOR TISSU
- Page 7 and 8:
that genetic toxicology data are ge
- Page 9 and 10:
well-orchestrated lung inflammation
- Page 11 and 12:
scribed in the literature. We have
- Page 13 and 14:
years ago). We will illustrate how
- Page 15 and 16:
involved in the biodegradation proc
- Page 17 and 18:
stem cells but rather a treatment i
- Page 19 and 20:
additional compound showed agreemen
- Page 21 and 22:
82 COMPARISON OF 3H-THYMIDINE INCOR
- Page 23 and 24:
irritants. While in practice these
- Page 25 and 26:
alleles are especially vulnerable t
- Page 27 and 28:
109 CD4+ T CELL INTRINSIC TNF RECEP
- Page 29 and 30:
118 TO STUDY THE SIGNAL TRANSDUCTIO
- Page 31 and 32:
PAHs, such as dioxins, are prevalen
- Page 33 and 34:
containing substituents and/or hydr
- Page 35 and 36:
146 COMPUTATIONAL MODELING FOR QT P
- Page 37 and 38:
suggest that the combination of too
- Page 39 and 40:
164 TRANSLOCATOR PROTEIN (18 KDA) (
- Page 41 and 42:
function as a metal binding protein
- Page 43 and 44:
laboratory has demonstrated that NR
- Page 45 and 46:
known. The aim of this study was to
- Page 47 and 48:
from 5 to 28 days in duration) in e
- Page 49 and 50:
positive cells, caspase-3 activatio
- Page 51 and 52:
creased level in the 46 kDa preproe
- Page 53 and 54:
invasiveness at concentrations repr
- Page 55 and 56:
thracene (DMBA,50 μg in acetone, a
- Page 57 and 58:
247 CO-CARCINOGENESIS OF N, N- DIET
- Page 59 and 60:
sponds to the endosomal dsRNA that
- Page 61 and 62:
ODD in both WT (maximum 177% of con
- Page 63 and 64:
Lastly, using p53siRNA cells, p53 w
- Page 65 and 66:
its receptor Mpl to exert its funct
- Page 67 and 68:
294 LOW LEVEL OF LEAD CAN INDUCE PH
- Page 69 and 70:
lunar surface presented potential h
- Page 71 and 72:
lar about cellular export mechanism
- Page 73 and 74:
DNA in the kidney medulla, grandula
- Page 75 and 76:
5.00 and 7.50 mg/kg/day by oral gav
- Page 77 and 78:
events and carcinogenesis. Here we
- Page 79 and 80:
tinization of cells of the hair fol
- Page 81 and 82:
358 CHARACTERIZATION OF GENOME-WIDE
- Page 83 and 84:
RNAi were also performed to identif
- Page 85 and 86:
376 A FUNCTIONAL CROSSTALK BETWEEN
- Page 87 and 88:
UGT1A gene induction, while this re
- Page 89 and 90:
tivity, specifically peroxisome pro
- Page 91 and 92:
and cytotoxic effects; however, its
- Page 93 and 94:
histone deacetylase that is necessa
- Page 95 and 96:
ment. Paradoxically, buthionine sul
- Page 97 and 98:
drug leflunomide and its major (A77
- Page 99 and 100:
442 GENE EXPRESSION AND MORPHOLOGIC
- Page 101 and 102:
451 INHIBITION OF THE MITOCHONDRIAL
- Page 103 and 104:
460 SULFORAPHANE PREVENTS ACETAMINO
- Page 105 and 106:
drophilic/lipophilic balance. Other
- Page 107 and 108:
pharmacokinetic and toxicological p
- Page 109 and 110:
489 USE OF ‘OMICS DATA TO IMPROVE
- Page 111 and 112:
498 APPLICATION OF AGE-SPECIFIC ADJ
- Page 113 and 114:
507 A DOSE VOLUME TOLERABILITY STUD
- Page 115 and 116:
involved the use of an acute inflam
- Page 117 and 118:
sorption in the gastrointestinal (G
- Page 119 and 120:
(ABC) transporters actively transpo
- Page 121 and 122:
545 BEHAVIORAL EFFECTS OF REPIN IN
- Page 123 and 124:
a blood pressure phenotype that res
- Page 125 and 126:
and inhalation exposure system that
- Page 127 and 128:
and lethality associated with these
- Page 129 and 130:
position, on vascular reactivity an
- Page 131 and 132:
therefore more accurate and reprodu
- Page 133 and 134:
commercial chrysotile product that
- Page 135 and 136:
elative to their controls. ST-depre
- Page 137 and 138:
ats. The majority of the studies fo
- Page 139 and 140:
in the China Jintan Child Cohort St
- Page 141 and 142:
corneum thickness, cellular epiderm
- Page 143 and 144:
645 EVALUATION OF THE IN VITRO EPIS
- Page 145 and 146:
654 TCDD ADSORBED ONTO NATURAL AND
- Page 147 and 148:
tion revealed no test article-relat
- Page 149 and 150:
671 INFLAMMATION AND TISSUE DAMAGE
- Page 151 and 152:
model, ethanol was found to inhibit
- Page 153 and 154:
689 ENHANCED SUPPRESSIVE FUNCTION O
- Page 155 and 156:
NAC + LPS yielded different levels
- Page 157 and 158:
707 LIFE-STAGE PBPK MODELS FOR MULT
- Page 159 and 160:
downstream of the apical endpoint o
- Page 161 and 162:
726 UPDATED ALUMINUM PHARMACOKINETI
- Page 163 and 164:
global parameter sensitivity analys
- Page 165 and 166:
and renal inflammation induced by 2
- Page 167 and 168:
754 PLASMA, URINE, AND TISSUE CONCE
- Page 169 and 170:
cently characterized transporter OA
- Page 171 and 172:
exposure system was developed from
- Page 173 and 174:
lood cell mass and decrease in urin
- Page 175 and 176:
practical alternatives to MC in non
- Page 177 and 178:
imals dosed with 167 mg/kg THU alon
- Page 179 and 180:
and organ weights, clinical signs a
- Page 181 and 182:
yet is induced in most bladder and
- Page 183 and 184:
830 RISK ASSESSMENT OF THE SPILL: C
- Page 185 and 186:
knowledgebase creation. Results are
- Page 187 and 188:
852 UNDERSTANDING STRUCTURAL AND PH
- Page 189 and 190:
for integrating epidemiology and an
- Page 191 and 192:
motor activity, including age of th
- Page 193 and 194:
y partial purification of urine (fr
- Page 195 and 196:
pacity for self-renewal and may dif
- Page 197 and 198:
sue. The depth of our analysis led
- Page 199 and 200:
910 IMPLEMENTING CALIFORNIA’S GRE
- Page 201 and 202:
concentrations in six tissues and b
- Page 203 and 204:
934 THE FDA’S LIVER TOXICITY KNOW
- Page 205 and 206:
943 GENOME-WIDE DNA METHYLATION DIF
- Page 207 and 208:
membrane localization and subsequen
- Page 209 and 210:
trols, respectively. Subtoxic and t
- Page 211 and 212:
survival using both smoking regimes
- Page 213 and 214:
as non-, weak, moderate, or strong
- Page 215 and 216:
988 NNK-INDUCED CYTOKINE ALTERATION
- Page 217 and 218:
group (one-way ANOVA, p90 % viabili
- Page 219 and 220:
ered as an organ involved in xenobi
- Page 221 and 222:
Transport of CPZ across the Caco-2
- Page 223 and 224:
estrous cycle and sexual behavior d
- Page 225 and 226:
mRNA expression levels. Collectivel
- Page 227 and 228:
1043 THE EFFECTS OF ENDOCRINE DISRU
- Page 229 and 230:
1052 MONO-2-ETHYLHEXYL PHTHALATE IN
- Page 231 and 232:
Results: MC was variable within and
- Page 233 and 234:
UtSMCs. Phosphorylation of FoxO1 wa
- Page 235 and 236:
nonpregnant and pregnant diabetic m
- Page 237 and 238:
1089 PFOA-INDUCED LIVER EFFECTS IN
- Page 239 and 240:
events in the liver. AZD9056 was ev
- Page 241 and 242:
The peppermint oil caused a concent
- Page 243 and 244:
OA did not affect food consumption.
- Page 245 and 246:
1126 PERSISTENT DEVELOPMENTAL ARYLH
- Page 247 and 248:
1135 BACH2 BINDING TO Prdm1 AS A ME
- Page 249 and 250:
The purpose of this project was to
- Page 251 and 252:
one marrow. Since Chk1 is an attrac
- Page 253 and 254:
1163 THE MRNA AND MIRNA PROFILE OF
- Page 255 and 256:
have now compared the IC50 values b
- Page 257 and 258:
1181 ELUCIDATION OF FACTORS DETERMI
- Page 259 and 260:
enced by pre-exposure to cigarette
- Page 261 and 262: if abnormal PF was associated with
- Page 263 and 264: weight (P=0.016) and small for gest
- Page 265 and 266: portant cause of death, compared to
- Page 267 and 268: posure groups. However, the differe
- Page 269 and 270: Naphthalene is routinely analyzed i
- Page 271 and 272: 1245 SEASONAL CHARACTERIZATION OF H
- Page 273 and 274: 1255 URINARY T, T MUCONIC ACID LEVE
- Page 275 and 276: modating a reliable data evaluation
- Page 277 and 278: enzoquinone generate ROS and arylat
- Page 279 and 280: teins (e.g. C3, 4, and 5, APOB, VDB
- Page 281 and 282: 1293 TRANSFORMING GROWTH FACTOR BET
- Page 283 and 284: mation was decreased to the same le
- Page 285 and 286: 1312 EVALUATION OF THE SENSITIVITY
- Page 287 and 288: luted OFR and CRL. Culture media ex
- Page 289 and 290: urinary TCPy levels, blood and brai
- Page 291 and 292: activity. The dose-response curves
- Page 293 and 294: mice, each with 4 dose groups. One
- Page 295 and 296: exposure to both ATR and DACT has a
- Page 297 and 298: third tetratricopeptide repeats (TP
- Page 299 and 300: 7d. 28d after TMT injury there was
- Page 301 and 302: subunits. Each cell type was treate
- Page 303 and 304: 1394 COMPARATIVE EFFECTS OF METHYLM
- Page 305 and 306: 1403 GENOTOXICITY AND PRE-NEOPLASTI
- Page 307 and 308: vated only in high-dose-treated ani
- Page 309 and 310: 1421 DOSE-RESPONSE OF NAPHTHALENE-I
- Page 311: cisplatin; 1.2-, 1.9- and 2.9-fold
- Page 315 and 316: 1448 DEVELOPMENT OF A METHOD FOR QU
- Page 317 and 318: 1457 GLOBAL GENE PROFILING REVEALS
- Page 319 and 320: cluding mouse and human macrophage,
- Page 321 and 322: model of lung inflammation and host
- Page 323 and 324: 1484 NANOTOXICOLOGY AND NANOHEALTH
- Page 325 and 326: throughput in vitro approach was us
- Page 327 and 328: 1502 IMMUNOLOGICAL ASPECTS OF AN AN
- Page 329 and 330: (CIA) and the Streptococcal cell wa
- Page 331 and 332: sitizers were 100% concordant among
- Page 333 and 334: 1530 MINIMAL RISK LEVELS FOR STYREN
- Page 335 and 336: ical groups in the field of regulat
- Page 337 and 338: vitro with this potentially insect-
- Page 339 and 340: their performance on toxicological
- Page 341 and 342: need for a better understanding of
- Page 343 and 344: 1577 AN IN VITRO MODEL SYSTEM FOR A
- Page 345 and 346: gene expression post-transcriptiona
- Page 347 and 348: 1595 GENE EXPRESSION PROFILE OF RAT
- Page 349 and 350: to confirm a hepatotoxic property o
- Page 351 and 352: 1613 AN INVESTIGATION OF THE CLEARA
- Page 353 and 354: its nuclear translocation was reduc
- Page 355 and 356: were collected from TK animals at d
- Page 357 and 358: egulated targets were selected for
- Page 359 and 360: U/L after tetracycline. Minocycline
- Page 361 and 362: peri-pubertal FasL-/- mice show a d
- Page 363 and 364:
showed similar levels of apoptosis
- Page 365 and 366:
1676 TWO BIOMARKERS FOR EVALUATION
- Page 367 and 368:
motifs selected. This system was ap
- Page 369 and 370:
1693 VOC SERUM LEVELS IN THE GENERA
- Page 371 and 372:
1702 DOES THE CLOCK MAKE THE POISON
- Page 373 and 374:
those with high nickel content are
- Page 375 and 376:
isk assessment. However, unique cha
- Page 377 and 378:
model of APAP metabolism and glutat
- Page 379 and 380:
logically & morphologically similar
- Page 381 and 382:
posure, blood chemistry was analyze
- Page 383 and 384:
elated to oxidative stress by measu
- Page 385 and 386:
ostasis), but work is needed to tra
- Page 387 and 388:
tokine products during carcinogenes
- Page 389 and 390:
ways as chemical stressors and, the
- Page 391 and 392:
toxicity of nanomaterials relates s
- Page 393 and 394:
1815 MEASURING COMPOUND SELECTIVITY
- Page 395 and 396:
1825 EFFECTS OF METABOLISM BY INTES
- Page 397 and 398:
cyanoacetic acid increased 2-3 fold
- Page 399 and 400:
1845 IS THE PROMISCUITY OF THE ARYL
- Page 401 and 402:
crorarray analysis. RT-PCR results
- Page 403 and 404:
are a family of phase-II biotransfo
- Page 405 and 406:
ous labs. As a result of positive s
- Page 407 and 408:
down the doses may produce more tox
- Page 409 and 410:
spectively. Below 100 mg/l of gemfi
- Page 411 and 412:
1900 GENERATION OF PRECISION CUT LI
- Page 413 and 414:
iomarkers or observation of lesions
- Page 415 and 416:
creased reticulocytes and lymphocyt
- Page 417 and 418:
statistically significant interacti
- Page 419 and 420:
monize sample preparation and analy
- Page 421 and 422:
NPC and sinonasal cancer in neighbo
- Page 423 and 424:
showed incidences of lung and nasal
- Page 425 and 426:
utylbenzenes, exhibited most simila
- Page 427 and 428:
1975 DIFFERENTIAL MODULATION OF CYP
- Page 429 and 430:
organic As to MMA(V) and a lower ca
- Page 431 and 432:
ole in invasion and metastasis of c
- Page 433 and 434:
3T3-L1 cells to low-levels of arsen
- Page 435 and 436:
2011 IDENTIFICATION OF A NOVEL VX M
- Page 437 and 438:
This work was supported by Cooperat
- Page 439 and 440:
2029 EFFICACY OF ENDOTRACHEAL ADMIN
- Page 441 and 442:
Diazepam injections and its combina
- Page 443 and 444:
2047 ESTERASE ACTIVITIES AND HEMOST
- Page 445 and 446:
nanoparticle-induced toxicity progr
- Page 447 and 448:
house, were iv infused into rats ov
- Page 449 and 450:
een explored. This study investigat
- Page 451 and 452:
croscopic analysis revealed that on
- Page 453 and 454:
egg yolk collected from turtles inh
- Page 455 and 456:
consistency of results in both expe
- Page 457 and 458:
2111 CYTOCHROME P450 3A5 GENOTYPE I
- Page 459 and 460:
esidues of organophosphates or thei
- Page 461 and 462:
manganism. Recent work from our lab
- Page 463 and 464:
Aβ1-40 in CSF and hippocampus in P
- Page 465 and 466:
2147 CATALASE MANIPULATIONS MODIFY
- Page 467 and 468:
ation based on real-world exposure
- Page 469 and 470:
NPs. Aggregation of citrate-stabili
- Page 471 and 472:
2175 THE ROLE OF SURFACE CHEMISTRY
- Page 473 and 474:
seen rapid uptake in biological ima
- Page 475 and 476:
effect on uterine weight or vaginal
- Page 477 and 478:
dicating widespread exposure. While
- Page 479 and 480:
components into the liver parenchym
- Page 481 and 482:
2223 ISOLATION AND DETECTION OF RIC
- Page 483 and 484:
stored (-20 celsius degree). The co
- Page 485 and 486:
2241 DDA, A BIOMARKER FOR ENVIRONME
- Page 487 and 488:
2249 INTERACTION BETWEEN DIETARY SE
- Page 489 and 490:
2258 PHARMACOKINETICS, EXCRETION BA
- Page 491 and 492:
2267 SENSITIVE AND SPECIFIC FLUORES
- Page 493 and 494:
2276 METABOLISM AND DISPOSITION OF
- Page 495 and 496:
ment of hypertension in companion a
- Page 497 and 498:
for the propyl series can be used f
- Page 499 and 500:
2304 IN VITRO EXPOSURE AND EVALUATI
- Page 501 and 502:
2313 THE SYNERGISTIC EFFECT OF SODI
- Page 503 and 504:
genes that play a crucial role in M
- Page 505 and 506:
2330 THE ROLE OF TRANSFORMING GROWT
- Page 507 and 508:
ined following up to 96 h continuou
- Page 509 and 510:
effect doses obtained with the rat
- Page 511 and 512:
diated transcriptional response of
- Page 513 and 514:
docrine disruptor activities of EDC
- Page 515 and 516:
individuals. Week 6 results were qu
- Page 517 and 518:
functionality of photosystem II and
- Page 519 and 520:
wild mice (Mus musculus) from areas
- Page 521 and 522:
2406 TOXICITY AND BIOACCUMULATION O
- Page 523 and 524:
Isocitric acid is the acid in the h
- Page 525 and 526:
2425 EFFECTS OF FUMONISINS IN ETHAN
- Page 527 and 528:
centration(μg/g) were: 5.1-95.3; 2
- Page 529 and 530:
2445 AUTOPHAGY IN DEVELOPMENT: A LI
- Page 531 and 532:
sures to inhaled Mn in dust. Nevert
- Page 533 and 534:
2466 CRITICAL EVALUATION OF ANIMAL
- Page 535 and 536:
elationships predict that resting r
- Page 537 and 538:
2489 COMPARATIVE TOXICITY OF BIODIE
- Page 539 and 540:
2497 TRANSCRIPTIONAL REGULATION OF
- Page 541 and 542:
2506 TOXICOLOGICAL CONSIDERATIONS O
- Page 543 and 544:
launched with the aim of developing
- Page 545 and 546:
forms mRNA expression levels were a
- Page 547 and 548:
2534 CUTANEOUS WOUND HEALING IN THE
- Page 549 and 550:
wells (0, 1, 5, 10, 25, 50, 100, an
- Page 551 and 552:
2553 AN ORGANOTYPIC MICROLIVER PLAT
- Page 553 and 554:
serum-free media. At 24 hrs, the gr
- Page 555 and 556:
2572 INCREASED ARSENIC BIOACCESSIBI
- Page 557 and 558:
nology to develop improved methods.
- Page 559 and 560:
tuna, swordfish, or mako shark (3.5
- Page 561 and 562:
nificantly reduce circulating thyro
- Page 563 and 564:
grouped into 9 observation periods
- Page 565 and 566:
histopathological or biochemical ev
- Page 567 and 568:
exhibited a hyperactive phenotype,
- Page 569 and 570:
the search of effective drugs for e
- Page 571 and 572:
2644 COVALENT BINDING OF 14 C 2-MET
- Page 573 and 574:
aries targeting all transcription f
- Page 575 and 576:
(p 9 weeks) and CSC phenotype acqui
- Page 577 and 578:
2673 IMMUNE-MEDIATED VASCULAR INJUR
- Page 579 and 580:
for risk identification and charact
- Page 581 and 582:
to control toxicant delivery in tob
- Page 583 and 584:
Author Index (Continued) The numera
- Page 585 and 586:
Author Index (Continued) The numera
- Page 587 and 588:
Author Index (Continued) The numera
- Page 589 and 590:
Author Index (Continued) The numera
- Page 591 and 592:
Author Index (Continued) The numera
- Page 593 and 594:
Author Index (Continued) The numera
- Page 595 and 596:
Author Index (Continued) The numera
- Page 597 and 598:
Author Index (Continued) The numera
- Page 599 and 600:
Author Index (Continued) The numera
- Page 601 and 602:
Author Index (Continued) The numera
- Page 603 and 604:
Author Index (Continued) The numera
- Page 605 and 606:
Author Index (Continued) The numera
- Page 607 and 608:
Author Index (Continued) The numera
- Page 609 and 610:
Author Index (Continued) The numera
- Page 611 and 612:
Keyword Index (Continued) Arsenite
- Page 613 and 614:
Keyword Index (Continued) Covalent
- Page 615 and 616:
Keyword Index (Continued) flow cyto
- Page 617 and 618:
Keyword Index (Continued) innate im
- Page 619 and 620:
Keyword Index (Continued) nanoparti
- Page 621 and 622:
Keyword Index (Continued) preservat
- Page 623 and 624:
Keyword Index (Continued) Thrombocy
- Page 625 and 626:
Toxicological Sciences The Official
Inappropriate
Loading...
Inappropriate
You have already flagged this document.
Thank you, for helping us keep this platform clean.
The editors will have a look at it as soon as possible.
Mail this publication
Loading...
Embed
Loading...
Delete template?
Are you sure you want to delete your template?
DOWNLOAD ePAPER
This ePaper is currently not available for download.
You can find similar magazines on this topic below under ‘Recommendations’.